Horizon Pharma Inc Announces FDA Approval of RAYOS

on .

Horizon Pharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved RAYOS® (prednisone) delayed-release tablets to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).